Welcome!

Cognitive Computing Authors: Liz McMillan, Yeshim Deniz, Elizabeth White, Pat Romanski, Amit Gupta

News Feed Item

Global Proteomics Industry

NEW YORK, Dec. 5, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

Global Proteomics Industry

http://www.reportlinker.com/p092466/Global-Proteomics-Industry.html#utm_...

 

This report analyzes the worldwide markets for Proteomics in US$ Million by the following Product Segments: Expression Proteomics, Functional Proteomics, and Structural Proteomics. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period of 2010 through 2015. Also, a six-year historic analysis is provided for these markets. The report profiles 111 companies including many key and niche players such as ActivX Biosciences, Inc., Adnexus Therapeutics, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Bruker Daltonics, Inc., Caprion Proteomics, Inc., Digilab Genomic Solutions, Inc., Dionex Corporation, GE Healthcare, Geneva Bioinformatics S.A., Hybrigenics SA, Life Technologies Corporation, Millipore Corp., PerkinElmer, Inc., Caliper Life Sciences, Shimadzu Biotech, Sigma-Aldrich Corporation, Thermo Fisher Scientific, Waters Corp., Xencor Inc., and Zyomyx, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

 

 

 

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-2

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

Expression Proteomics I-3

Functional Proteomics I-3

Structural Proteomics I-4

 

 

II. EXECUTIVE SUMMARY

 

1. GLOBAL MARKET OVERVIEW II-1

Proteomics - The Current Spotlight II-1

Market Drivers II-1

Transition from Genomics to Proteomics II-1

Industrialization of Proteomics Research II-2

International Initiatives Light-up Proteomics Market II-2

Factors Limiting Market Growth II-2

Economic Recession Impact on the Life Sciences Industry in

Retrospect II-2

Biotechnology Sector - Affected by Collapse of Capital Market II-3

Tough Times for Market Participants II-3

Proteomics Technologies: Growing in Significance II-4

Transformation of Drug Discovery through Proteomics and Genomics II-5

Proteomics: A Critical Drug Discovery Tool II-5

China All Set To Play a Major Role in the Proteomics Industry II-6

Global Proteomics Sample Preparation Market - On a Growth Curve II-7

Challenges Facing Proteomics Sample Preparation Market II-7

Challenges Facing Proteomics Industry II-7

Protein Chemistry and its Complexities II-7

Integration of Data & Equipment II-7

Data Validation - A Burning Issue II-8

Standardization & Consistency - A Prime Concern II-8

Incomplete and Disorganized Data II-8

 

2. INDUSTRY COMPETITION II-9

Industry Participants II-9

Proteomics Market Worldwide: Competitive Landscape II-9

Proteomics Supplier Market II-9

Tool Providers: Leading the Proteomics Market II-10

Applied Biosystems-Invitrogenc Corporation Merger - A Key

Development II-10

Challenges Ahead II-11

Designing a Novel Business Model II-11

Role of Contract Research Organizations - All Set to Increase

in Proteomics II-11

 

3. PRODUCT AND TECHNOLOGY OVERVIEW II-12

Proteins, Proteome and Proteomics!!! - What are They? II-12

Proteomics - An Introduction II-12

Genesis of Proteomics II-13

Tales From Times Gone By II-13

Components of Proteomics II-13

Expression Proteomics II-13

Functional Proteomics II-14

Cell-map Proteomics II-14

Structural Proteomics II-14

Technologies and Proteomics II-14

Proteomics and Genomics II-15

Proteomics and Genomics: A Comparison II-15

Protein Production Pathway: From Gene Expression to

Functional Protein with Controls II-15

From Genomics to Proteomics II-16

Functional Genomics and Proteomics II-16

Push From Genomic Information II-17

An Insight into Proteomics Data Type and their

Characteristics / Features II-17

Standard Proteomics Approach II-17

Sample Preparation - Step I II-18

Protein Separation - Step II II-18

Protein Visualization II-18

Protein Expression Analysis-Step III II-18

Protein Identification - Step IV II-19

Data Storage and Processing - Step V II-19

 

4. OVERVIEW OF PROTEOMICS TECHNOLOGIES II-20

A Snapshot of Various Proteomics Tools II-20

An Insight into Various Proteomics Technologies and their

Application Areas II-20

Protein Separation II-20

2-Dimensional Gel Electrophoresis (2DGE) II-20

Protein Characterization II-22

Analysis of Protein Through Mass Spectrometry II-22

MS and Proteins II-22

Applications of MS II-23

Problems Associated with MS II-24

Types of Analyzers or Filters II-24

Y2H, Yeast 2-Hybrid System II-25

Protein Microarrays II-26

Chip Technology II-26

Microfluidic Applications II-27

Role of Bioinformatics in Proteomics II-27

Bioinformatics Applications and Tools in Proteomics II-27

Emerging Proteomics Technologies II-29

MudPIT II-29

ICAT II-29

Phage Display Technique II-30

Advanced Proteomics Technologies: Structural Analysis Tools II-30

X-ray Crystallography II-30

Nuclear Magnetic Resonance (NMR) II-30

In silico Modelling II-31

Physicochemical Factors Constraining Metabolic Functions II-31

 

5. END-USE APPLICATION AREAS II-32

Proteomics in Drug and Diagnostic Discovery II-33

Proteomics and Drug Discovery II-33

Protein Microarrays: A New Tool for the Development of

Pharmaceuticals II-34

Proteomic Approaches Gain Prominence in Cancer Drug Discovery II-34

Advancements in Proteomics Bring Biomarkers into Limelight II-35

 

6. NEW PRODUCT SOLUTIONS/ DEVELOPMENTS II-36

Applied Biomics Introduces Global Protein Post- Translational

Modification II-36

AB SCIEX Launches New Column Chips II-36

Applied Biomics Introduces New Mass Spectrometry Service II-37

Norton Scientific Introduces Novel Specialist Applications

Development Laboratory Service II-37

Gentel Biosciences Introduces APiXTM Disease Profiling Kit II-38

Integromics Introduces OmicsHub Proteomics 2.0 II-38

Bruker Introduces amaZon Speed Ion Trap Mass Spectrometers II-39

Applied Biomics Introduces iTRAQ Service for Proteomics Research II-39

Norton Scientifc Company Introduces New Lab Support Service

for Rapid RNA/DNA and Protein Measurement II-39

Bruker Launches MALDI BiotargetTM II-40

Thermo Fisher Launches UHLPC System II-40

Kinexus Introduces Human Gene Online TranscriptoNET KnowledgeBase II-41

Bruker Launches PRIME Integrated Proteomics Solution II-42

Applied Biosystems Launches LS*LIMS Laboratory Automation

Technology for Proteomics and Genomics II-42

Kinexus Bioinformatics Introduces Online KiNET-AM Proteomics

DataBase II-42

Bruker Rolls Out CaptiveSpray Electrospray Ion Source for

Proteomics Applications II-43

Thermo Fisher Launches New Capabilities for Performing

Proteomics Workflows II-43

National Cancer Institute Introduces Clinical Proteomic Tumor

Analysis Consortium for Cancer Studies II-44

KinaSorbTM' - New Kit for Kinase Enrichment II-45

 

7. PRODUCT INTRODUCTIONS/INNOVATIONS IN RECENT PAST - A

PERSPECTIVE BUILDER II-46

Gentel Biosciences Unveils Gentel Proteomics Multi-SystemTM II-46

caprotec bioanalytics Introduces Innovative caproKits II-46

Gentel Biosciences Introduces SilverQuant® Simian Pathogen

Array for Health Monitoring of Laboratory Animals II-46

Gentel Biosciences Introduces SilverQuant® Human Tumor

Profiling Kits II-46

Gentel Biosciences Introduces SilverQuant® Disease Profiling Kit II-47

Gentel Biosciences Introduces SilverQuant® View Detection Kits II-47

Gentel Biosciences Launches Proteomics Multi-System II-47

New England Peptide Introduces NEPTune™ Range of Proteomics

Reagents II-48

Applied Biomics Introduces NanoLC-MS/MS Service II-48

Life Technologies Introduces Magic Sample Processor for

Epigenetics, Proteomics Sample Preparation II-49

Integromics Introduces SeqSolve™ NGS Bioinformatics Analysis

Software II-50

Thermo Fisher Scientific Unveils Software Suite for Enhanced

Workflows in Proteomics II-50

Proxeon Introduces EASY-nLC II System for Improved

Productivity in Proteomics (Denmark) II-51

Gentel Biosciences Launches Proteomics Multi-System II-51

Arrayit Discovers New Proteomic Biomarkers II-52

Kinexus Bioinformatics Launches Peptide Development Facility II-52

Bruker Daltonics Unveils ultrafleXtreme™ MALDI-TOF/TOF Mass

Spectrometer II-52

Agilent Technologies Rolls Out HPLC-Chip II-53

Applied Biosystems and MDS Introduce AB SCIEX TOF/TOF™ 5800

System II-53

Applied Biomics Extends Proteomics Service Offerings II-54

AnaSpec Introduces Keratin Antibodies II-54

caprotec bioanalytics Unveils cAMP caproKit and SAH caproKit II-54

Huzhou Sai'erdi Biopharmaceutical Introduces Proteomic

Fingerprint Technology Test Kit II-54

 

8. RECENT INDUSTRY ACTIVITY II-55

Life Technologies Enters into Partnership with Sino Biological II-55

Proteome Sciences Signs Agreement with CHDI Foundation II-55

Waters Corp. Inks Agreement with Nonlinear Dynamics II-56

BioFocus Enters into Alliance with Activiomics II-56

Great Point Partners Divests Caprion Proteomics II-56

Glaxo Smith Kline Takes Over Cellzome II-57

Emerald BioSystems Changes Name to Emerald Bio II-57

Bruker Unveils Novel Nano-Advance UHPLC System II-57

Evotec Takes Over Kinaxo Biotechnologies II-58

Kinaxo Biotechnologies and AstraZeneca Sign Agreement II-58

Gentel Biosciences Takes Over Eppendorf's SilverQuant Trademark II-58

Thermo Fisher Takes Over Fermentas International II-58

KINAXO to Collaborate with Takeda II-59

Dualsystems and Bulldog Bio Signs Exclusive Marketing Agreement II-59

Novartis Enters into Agreement with SomaLogic II-59

Sage-N Inks Exclusive Pact With the U.S. Army II-59

Proteome Sciences Inks Agreement with Moffitt Cancer Center II-60

Gentel Biosciences Enters into Agreement with Oregon Health &

Science University II-60

Evotec OAI Forms Joint Venture with MeITec to Collaborate on

Drug Discovery Services II-60

 

9. CORPORATE ACTIVITY IN RECENT PAST - A PERSPECTIVE BUILDER II-61

MicroBioChips Merges with Biosystems II-61

Caprion Proteomics Acquires Biomarket Unit from PPD Biomarker

Discovery Sciences II-61

ICON Enters into Strategic Alliance with Proteome Sciences II-61

Gentel Enters into Partnership with RayBiotech for

SilverQuant® Chromogenic Detection Platform II-61

Trans-Hit Biomarkers Enters into Alliance with Caprion to

Deliver Proteome-Hit Services II-62

Proteoprep Enters into License Agreement with Sigma-Aldrich II-62

Activiomics Signs Technology Agreement with UCB for Proteomics

Platform(UK/Belgium) II-63

Expression Pathology Enters into Service Partnership with

Flagship for Tissue Proteomics Development II-63

National Cancer Institute Enters into MoU with AACC in

Proteomics Sector II-63

MGL Americas and ProFACT Proteomics Team Up for Biomarker

Discovery II-64

Thermo Fisher Scientific and Luxembourg Clinical Proteomics

Unit Form Collaboration (Luxembourg) II-64

Covance Unveils Discovery and Translational Services Division II-65

Thermo Fisher Scientific Takes Over Proxeon II-65

TriLink BioTechnologies and Nacalai USA Sign Distribution

Agreement II-65

Cell Biosciences Takes Over Alpha Innotech II-65

Eurogentec to Take Over Ana Spec II-66

Merck Takes Over Bangalore Genei II-66

Cell Biosciences Takes Over Protein Forest II-66

Microsoft to Acquire Rosetta Bio Software Assets II-67

CCMB and Bio-Rad India Sign MoU II-67

SAIC-Frederick and Sensor Technologies Ink Collaboration

Agreement II-67

NuSep Signs Purchase Agreement with BioInquire II-68

Intrinsic Bioprobes Bags Contract from NCI II-68

HORIBA Jobin Yvon Acquires GenOptics II-68

Gentel Biosciences Partners with Eprogen II-68

Bruker Daltonics Installs High-Field 15 Tesla and 12 Tesla

FTMS Systems at LUMC II-69

Genedata Extends Collaboration with Roche II-69

AliX Merges with Novalyst Discovery to form NovAliX II-70

BioPike and AnaSpec Sign Agreement II-70

Sigma-Aldrich Purchases Electrophoresis Business of NextGen

Sciences II-70

Fujifilm Purchases Additional Stake in Perseus Proteomics II-71

Sigma-Aldrich Buys Seppro® Depletion Technology and 700

Antibodies II-71

Oxford Gene Technology Purchases Sense Proteomic II-72

Center for Cancer Research Acquires Waters® UPLC/MS Systems II-72

 

10. FOCUS ON SELECT KEY PLAYERS II-74

ActivX Biosciences, Inc. (US) II-74

Adnexus Therapeutics (US) II-74

Agilent Technologies, Inc. (US) II-74

Bio-Rad Laboratories, Inc. II-74

Bruker Daltonics, Inc. (US) II-75

Caprion Proteomics, Inc. (Canada) II-75

Digilab Genomic Solutions, Inc. (US) II-76

Dionex Corporation (US) II-76

GE Healthcare (United Kingdom) II-76

Geneva Bioinformatics S.A. (Switzerland) II-76

Hybrigenics SA (France) II-76

Life Technologies Corporation (US) II-77

Millipore Corp. (US) II-77

PerkinElmer, Inc. (US) II-78

Caliper Life Sciences (US) II-78

Shimadzu Biotech (Japan) II-78

Sigma-Aldrich Corporation (US) II-78

Thermo Fisher Scientific (US) II-79

Waters Corp. (US) II-79

Xencor Inc. (US) II-80

Zyomyx, Inc. (US) II-80

 

11. GLOBAL MARKET PERSPECTIVE II-81

Table 1: World Recent Past, Current & Future Analysis for

Proteomics by Geographic Region - US, Canada, Japan, Europe

and Rest of World Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2010 through 2018

(includes corresponding Graph/Chart) II-81

 

Table 2: World Historic Review for Proteomics by Geographic

Region - US, Canada, Japan, Europe and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2004 through 2009 (includes corresponding

Graph/Chart) II-82

 

Table 3: World 15-Year Perspective for Proteomics by

Geographic Region - Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe and Rest of World Markets for Years

2004, 2011 and 2018 (includes corresponding Graph/Chart) II-83

 

Table 4: World Recent Past, Current & Future Analysis for

Proteomics by Segment - Expression Proteomics, Functional

Proteomics and Structural Proteomics Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2010 through 2018 (includes corresponding Graph/Chart) II-84

 

Table 5: World Historic Review for Proteomics by Segment -

Expression Proteomics, Functional Proteomics and Structural

Proteomics Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2004 through 2009 (includes

corresponding Graph/Chart) II-85

 

Table 6: World 15-Year Perspective for Proteomics by Segment -

Percentage Breakdown of Dollar Sales for Expression

Proteomics, Functional Proteomics and Structural Proteomics

Markets for Years 2004, 2011 and 2018 (includes corresponding

Graph/Chart) II-86

 

12. GLOSSARY OF TERMS II-87

1-D, 2-D, 3-D II-87

Atmospheric Pressure Ionisation II-87

Electrophoresis II-87

Functional Genomics II-87

High-Throughput II-87

Liquid Chromatography (LC) II-87

Mass Spectrometry (MS) II-87

Matrix-Assisted Laser Desorption Ionisation (MALDI) II-87

Nuclear Magnetic Resonance II-88

X-ray Diffraction II-88

Yeast Two-Hybrid System II-88

2D-PAGE (Two-dimensional PolyAcrylamide Gel Electrophoresis) II-88

TOF (Time of Flight) II-88

Quadrupole II-88

Q-TOF (Quadrupole Time of Flight) II-88

ESI (Electrospray Ionisation) II-88

 

 

III. MARKET

 

1. THE UNITED STATES III-1

A.Market Analysis III-1

Outlook III-1

Proteomics Sample Preparation Market III-1

New Product Developments III-1

Strategic Corporate Developments III-6

Select Key Players III-9

B.Market Analytics III-14

Table 7: The US Recent Past, Current & Future Analysis for

Proteomics Market Analyzed with Annual Sales Figures in US$

Million for Years 2010 through 2018 (includes corresponding

Graph/Chart) III-14

 

Table 8: The US Historic Review for Proteomics Market

Analyzed with Annual Sales Figures in US$ Million for Years

2004 through 2009 (includes corresponding Graph/Chart) III-15

 

2. CANADA III-16

A.Market Analysis III-16

Outlook III-16

New Product Developments III-16

Strategic Corporate Development III-18

Caprion Proteomics, Inc. - A Key Player III-18

B.Market Analytics III-19

Table 9: Canadian Recent Past, Current & Future Analysis for

Proteomics Market Analyzed with Annual Sales Figures in US$

Million for Years 2010 through 2018 (includes corresponding

Graph/Chart) III-19

 

Table 10: Canadian Historic Review for Proteomics Market

Analyzed with Annual Sales Figures in US$ Million for Years

2004 through 2009 (includes corresponding Graph/Chart) III-20

 

3. JAPAN III-21

A.Market Analysis III-21

Shimadzu Biotech - A Key Player III-21

B.Market Analytics III-21

Table 11: Japanese Recent Past, Current & Future Analysis

for Proteomics Market Analyzed with Annual Sales Figures in

US$ Million for Years 2010 through 2018 (includes

corresponding Graph/Chart) III-21

 

Table 12: Japanese Historic Review for Proteomics Market

Analyzed with Annual Sales Figures in US$ Million for Years

2004 through 2009 (includes corresponding Graph/Chart) III-22

 

4. EUROPE III-23

A.Market Analysis III-23

Outlook III-23

Proteomics Research in Europe - An Overview III-23

Table 13: European Proteomics Market (2011): Percentage

Breakdown of Deployment of Proteomics Technologies in

End-Use Segments - Research and Academic Institutions,

Pharmaceutical Companies and Clinical Laboratories

(includes corresponding Graph/Chart) III-24

Protein Identification Market III-24

Protein Separation Market III-24

Market Challenges III-25

Gaining Edge in the Proteomics Industry - Player Strategies III-25

European 2DE Market - Benefiting from Recession III-26

Review of Select Markets III-26

Germany III-26

The United Kingdom III-26

New Product Developments III-27

Strategic Corporate Developments III-28

Select Key Players III-30

B.Market Analytics III-31

Table 14: European Recent Past, Current & Future Analysis

for Proteomics by Geographic Region - France, Germany, UK

and Rest of Europe Markets Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2010 through

2018 (includes corresponding Graph/Chart) III-31

 

Table 15: European Historic Review for Proteomics by

Geographic Region - France, Germany, UK and Rest of Europe

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2004 through 2009 (includes

corresponding Graph/Chart) III-32

 

Table 16: European 15-Year Perspective for Proteomics by

Geographic Region - Percentage Breakdown of Dollar Sales for

France, Germany, UK andRest of Europe Markets for Years

2004, 2011 and 2018 (includes corresponding Graph/Chart) III-33

 

5. REST OF WORLD III-34

A.Market Analysis III-34

Outlook III-34

Australia III-34

India III-34

Indian Scientific Research towards Functional Genomics and

Proteomics III-34

B.Market Analytics III-35

Table 17: Rest of World Recent Past, Current & Future

Analysis for Proteomics Market Analyzed with Annual Sales

Figures in US$ Million for Years 2010 through 2018 (includes

corresponding Graph/Chart) III-35

 

Table 18: Rest of World Historic Review for Proteomics

Market Analyzed with Annual Sales Figures in US$ Million for

Years 2004 through 2009 (includes corresponding Graph/Chart) III-36

 

 

IV. COMPETITIVE LANDSCAPE

 

Total Companies Profiled: 111 (including Divisions/Subsidiaries - 128)

 

The United States (82)

Canada (4)

Japan (3)

Europe (39)

- France (3)

- Germany (10)

- The United Kingdom (13)

- Spain (1)

- Rest of Europe (12)

 

 

 

To order this report:

Drug_Discovery_and_Development Industry: Global Proteomics Industry

 

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

 

 

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
DXWorldEXPO LLC, the producer of the world's most influential technology conferences and trade shows has announced the 22nd International CloudEXPO | DXWorldEXPO "Early Bird Registration" is now open. Register for Full Conference "Gold Pass" ▸ Here (Expo Hall ▸ Here)
"We are a well-established player in the application life cycle management market and we also have a very strong version control product," stated Flint Brenton, CEO of CollabNet,, in this SYS-CON.tv interview at 18th Cloud Expo at the Javits Center in New York City, NY.
In his session at @ThingsExpo, Arvind Radhakrishnen discussed how IoT offers new business models in banking and financial services organizations with the capability to revolutionize products, payments, channels, business processes and asset management built on strong architectural foundation. The following topics were covered: How IoT stands to impact various business parameters including customer experience, cost and risk management within BFS organizations.
Here are the Top 20 Twitter Influencers of the month as determined by the Kcore algorithm, in a range of current topics of interest from #IoT to #DeepLearning. To run a real-time search of a given term in our website and see the current top influencers, click on the topic name. Among the top 20 IoT influencers, ThingsEXPO ranked #14 and CloudEXPO ranked #17.
While the focus and objectives of IoT initiatives are many and diverse, they all share a few common attributes, and one of those is the network. Commonly, that network includes the Internet, over which there isn't any real control for performance and availability. Or is there? The current state of the art for Big Data analytics, as applied to network telemetry, offers new opportunities for improving and assuring operational integrity. In his session at @ThingsExpo, Jim Frey, Vice President of S...
With the introduction of IoT and Smart Living in every aspect of our lives, one question has become relevant: What are the security implications? To answer this, first we have to look and explore the security models of the technologies that IoT is founded upon. In his session at @ThingsExpo, Nevi Kaja, a Research Engineer at Ford Motor Company, discussed some of the security challenges of the IoT infrastructure and related how these aspects impact Smart Living. The material was delivered interac...
Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settlement products to hedge funds and investment banks. After, he co-founded a revenue cycle management company where he learned about Bitcoin and eventually Ethereal. Andrew's role at ConsenSys Enterprise is a mul...
Amazon started as an online bookseller 20 years ago. Since then, it has evolved into a technology juggernaut that has disrupted multiple markets and industries and touches many aspects of our lives. It is a relentless technology and business model innovator driving disruption throughout numerous ecosystems. Amazon’s AWS revenues alone are approaching $16B a year making it one of the largest IT companies in the world. With dominant offerings in Cloud, IoT, eCommerce, Big Data, AI, Digital Assista...
In his session at Cloud Expo, Alan Winters, U.S. Head of Business Development at MobiDev, presented a success story of an entrepreneur who has both suffered through and benefited from offshore development across multiple businesses: The smart choice, or how to select the right offshore development partner Warning signs, or how to minimize chances of making the wrong choice Collaboration, or how to establish the most effective work processes Budget control, or how to maximize project result...
The Founder of NostaLab and a member of the Google Health Advisory Board, John is a unique combination of strategic thinker, marketer and entrepreneur. His career was built on the "science of advertising" combining strategy, creativity and marketing for industry-leading results. Combined with his ability to communicate complicated scientific concepts in a way that consumers and scientists alike can appreciate, John is a sought-after speaker for conferences on the forefront of healthcare science,...
In his keynote at 19th Cloud Expo, Sheng Liang, co-founder and CEO of Rancher Labs, discussed the technological advances and new business opportunities created by the rapid adoption of containers. With the success of Amazon Web Services (AWS) and various open source technologies used to build private clouds, cloud computing has become an essential component of IT strategy. However, users continue to face challenges in implementing clouds, as older technologies evolve and newer ones like Docker c...
When shopping for a new data processing platform for IoT solutions, many development teams want to be able to test-drive options before making a choice. Yet when evaluating an IoT solution, it’s simply not feasible to do so at scale with physical devices. Building a sensor simulator is the next best choice; however, generating a realistic simulation at very high TPS with ease of configurability is a formidable challenge. When dealing with multiple application or transport protocols, you would be...
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at Cloud Expo, Ed Featherston, a director and senior enterprise architect at Collaborative Consulting, discussed the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
Personalization has long been the holy grail of marketing. Simply stated, communicate the most relevant offer to the right person and you will increase sales. To achieve this, you must understand the individual. Consequently, digital marketers developed many ways to gather and leverage customer information to deliver targeted experiences. In his session at @ThingsExpo, Lou Casal, Founder and Principal Consultant at Practicala, discussed how the Internet of Things (IoT) has accelerated our abilit...
Detecting internal user threats in the Big Data eco-system is challenging and cumbersome. Many organizations monitor internal usage of the Big Data eco-system using a set of alerts. This is not a scalable process given the increase in the number of alerts with the accelerating growth in data volume and user base. Organizations are increasingly leveraging machine learning to monitor only those data elements that are sensitive and critical, autonomously establish monitoring policies, and to detect...
Dion Hinchcliffe is an internationally recognized digital expert, bestselling book author, frequent keynote speaker, analyst, futurist, and transformation expert based in Washington, DC. He is currently Chief Strategy Officer at the industry-leading digital strategy and online community solutions firm, 7Summits.
Two weeks ago (November 3-5), I attended the Cloud Expo Silicon Valley as a speaker, where I presented on the security and privacy due diligence requirements for cloud solutions. Cloud security is a topical issue for every CIO, CISO, and technology buyer. Decision-makers are always looking for insights on how to mitigate the security risks of implementing and using cloud solutions. Based on the presentation topics covered at the conference, as well as the general discussions heard between sessio...
Recently, REAN Cloud built a digital concierge for a North Carolina hospital that had observed that most patient call button questions were repetitive. In addition, the paper-based process used to measure patient health metrics was laborious, not in real-time and sometimes error-prone. In their session at 21st Cloud Expo, Sean Finnerty, Executive Director, Practice Lead, Health Care & Life Science at REAN Cloud, and Dr. S.P.T. Krishnan, Principal Architect at REAN Cloud, discussed how they built...
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settl...
IoT solutions exploit operational data generated by Internet-connected smart “things” for the purpose of gaining operational insight and producing “better outcomes” (for example, create new business models, eliminate unscheduled maintenance, etc.). The explosive proliferation of IoT solutions will result in an exponential growth in the volume of IoT data, precipitating significant Information Governance issues: who owns the IoT data, what are the rights/duties of IoT solutions adopters towards t...